Company Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment.
Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.
The company’s pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica.
The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | George K. Ng Esq., J.D. |
Contact Details
Address: 7380 Coca Cola Drive, Suite 106 Hanover, Maryland 21076 United States | |
| Phone | 443-776-3133 |
| Website | processapharmaceuticals.com |
Stock Details
| Ticker Symbol | PCSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533743 |
| CUSIP Number | 74275C205 |
| ISIN Number | US74275C3043 |
| Employer ID | 45-1539785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George K. Ng Esq., J.D. | Chief Executive Officer |
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, President of Research and Development and Director |
| Dr. Sian E. Bigora Ph.D., Pharm.D. | Co-Founder and Chief Development and Regulatory Officer |
| James H. Stanker | Chief Financial Officer |
| Patrick Lin | Co-Founder, Chief Business and Strategy Officer |
| Wendy J. Guy | Co-Founder, Chief Administrative Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 8-K | Current Report |
| Jul 2, 2024 | 8-K | Current Report |
| Jun 11, 2024 | DEFR14A | Filing |
| May 28, 2024 | EFFECT | Notice of Effectiveness |
| May 28, 2024 | 424B5 | Filing |
| May 23, 2024 | UPLOAD | Filing |
| May 21, 2024 | 8-K | Current Report |
| May 21, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 10, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |